Aragoneses Federico G, Moreno N, Leon P, Fontan E G, Folque E
Department of Thoracic Surgery, Hospital General Universitario Gregorio Marañon, Dr Esquerdo, 46 28007 Madrid, Spain.
Lung Cancer. 2002 Apr;36(1):59-63. doi: 10.1016/s0169-5002(01)00458-5.
The objective of the study was to find out whether the delay in time from when bronchogenic carcinoma is diagnosed until a therapeutic thoracotomy is performed affects patient survival. The population analysed comprised 1082 patients with clinical stage I and II, non-small cell lung cancer (NSCLC), who had been operated on between October 1993 and September 1997, and were registered in the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). In this series, the median therapeutic delay was 35 days (1-154), with a median survival rate of 52 months (45.6-58.3). A statistical study was developed that, in addition to the delay, included the variables of age, histology, clinical stage, and pathological stage of the disease. Therapeutic delay was included in the multivariable analysis as a quantitative and qualitative variable and a comparison among the different intervals of delay in days (1-20 vs. 21-40 vs. 41-60 vs. > 60) was performed in order to ascertain its influence on survival. Univariate and multivariate Cox's regression analyses showed that age (> 70 years), clinical stage (I vs. II), and pathological stage influence survival. As for the histology and the delay, no significant differences were observed in the survival of any of the intervals even when compared against the intervals at the extremes (1-20 vs. > 60). In conclusion we found no influence of delay upon the survival.
该研究的目的是查明从支气管源性癌确诊到进行治疗性开胸手术之间的时间延迟是否会影响患者的生存率。所分析的人群包括1082例临床I期和II期非小细胞肺癌（NSCLC）患者，他们于1993年10月至1997年9月期间接受了手术，并登记在西班牙肺科和胸外科协会支气管源性癌合作组（GCCB-S）中。在这个系列中，治疗延迟的中位数为35天（1 - 154天），中位生存率为52个月（45.6 - 58.3个月）。开展了一项统计研究，除延迟外，该研究还纳入了年龄、组织学、临床分期和疾病病理分期等变量。治疗延迟作为定量和定性变量纳入多变量分析，并对按天数划分的不同延迟区间（1 - 20天 vs. 21 - 40天 vs. 41 - 60天 vs. > 60天）进行比较，以确定其对生存率的影响。单因素和多因素Cox回归分析表明，年龄（> 70岁）、临床分期（I期 vs. II期）和病理分期会影响生存率。至于组织学和延迟情况，即使将各区间与两端的区间（1 - 20天 vs. > 60天）进行比较，在任何区间的生存率方面均未观察到显著差异。总之，我们发现延迟对生存率没有影响。
